Impact of hepatocellular carcinoma-related prognostic factors on combined hepatocellular cholangiocarcinoma: A surgical cohort study.
코호트
1/5 보강
PICO 자동 추출 (휴리스틱, conf 3/4)
유사 논문P · Population 대상 환자/모집단
80 patients with cHCC-CC and 160 patients with HCC for comparative analysis of clinicopathological characteristics and surgical outcomes.
I · Intervention 중재 / 시술
standard hepatectomy between January 2002 and November 2024 for preoperatively diagnosed cHCC-CC or HCC
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
Our findings suggest that HCC-related prognostic factors significantly influence cHCC-CC progression and recurrence, emphasizing that cHCC-CC may represent an aggressive variant of HCC.
ℹ️ 이 논문은 무료 전문이 아직 없습니다. 코퍼스 전체의 44.0%는 무료 가능 (통계 →) · 🏥 기관 EZproxy로 시도
[INTRODUCTION] Combined hepatocellular cholangiocarcinoma (cHCC-CC) exhibits features of hepatocellular carcinoma (HCC) and cholangiocarcinoma.
- p-value p < 0.001
- p-value p = 0.012
APA
Chen PD, Su TW, et al. (2025). Impact of hepatocellular carcinoma-related prognostic factors on combined hepatocellular cholangiocarcinoma: A surgical cohort study.. European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 51(9), 110279. https://doi.org/10.1016/j.ejso.2025.110279
MLA
Chen PD, et al.. "Impact of hepatocellular carcinoma-related prognostic factors on combined hepatocellular cholangiocarcinoma: A surgical cohort study.." European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, vol. 51, no. 9, 2025, pp. 110279.
PMID
40618639 ↗
Abstract 한글 요약
[INTRODUCTION] Combined hepatocellular cholangiocarcinoma (cHCC-CC) exhibits features of hepatocellular carcinoma (HCC) and cholangiocarcinoma. However, whether HCC-related prognostic factors are involved in cHCC-CC remains inconclusive. This study aimed to compare the pathophysiology and recurrence factors between cHCC-CC and HCC.
[MATERIALS AND METHODS] We retrospectively analyzed 1274 consecutive patients who underwent standard hepatectomy between January 2002 and November 2024 for preoperatively diagnosed cHCC-CC or HCC. Propensity score matching (1:2) yielded 80 patients with cHCC-CC and 160 patients with HCC for comparative analysis of clinicopathological characteristics and surgical outcomes.
[RESULTS] The 10-year overall survival was 11.3 % for cHCC-CC vs. 17.5 % for HCC (p < 0.001), whereas the 10-year disease-free survival was 10.0 % vs. 15.6 % (p = 0.012). Early recurrence occurred in 27.5 % of cHCC-CC cases vs. 12.5 % of HCC cases. Compared to HCC, cHCC-CC showed higher prevalence of high-grade tumors (55.0 % vs. 39.4 %, p = 0.031), lack of tumor encapsulation (2.3 % vs. 14.5 %, p = 0.031), tumor necrosis (58.3 % vs. 37.8 %, p = 0.02), vascular invasion (51.3 % vs. 39.3 %, p = 0.028), lymphovascular and perineural invasion (both p < 0.001), and lymph node metastasis (7.5 % vs. 1.3 %, p = 0.009). Early recurrence was significantly associated with a higher prevalence of tumor necrosis (p = 0.002), aggressive vascular invasion (p = 0.006), satellite nodules (27.3 % vs. 6.9 %, p = 0.009), and advanced tumor stage (T3-T4: 27.3 % vs. 10.3 %, p = 0.003).
[CONCLUSION] Our findings suggest that HCC-related prognostic factors significantly influence cHCC-CC progression and recurrence, emphasizing that cHCC-CC may represent an aggressive variant of HCC.
[MATERIALS AND METHODS] We retrospectively analyzed 1274 consecutive patients who underwent standard hepatectomy between January 2002 and November 2024 for preoperatively diagnosed cHCC-CC or HCC. Propensity score matching (1:2) yielded 80 patients with cHCC-CC and 160 patients with HCC for comparative analysis of clinicopathological characteristics and surgical outcomes.
[RESULTS] The 10-year overall survival was 11.3 % for cHCC-CC vs. 17.5 % for HCC (p < 0.001), whereas the 10-year disease-free survival was 10.0 % vs. 15.6 % (p = 0.012). Early recurrence occurred in 27.5 % of cHCC-CC cases vs. 12.5 % of HCC cases. Compared to HCC, cHCC-CC showed higher prevalence of high-grade tumors (55.0 % vs. 39.4 %, p = 0.031), lack of tumor encapsulation (2.3 % vs. 14.5 %, p = 0.031), tumor necrosis (58.3 % vs. 37.8 %, p = 0.02), vascular invasion (51.3 % vs. 39.3 %, p = 0.028), lymphovascular and perineural invasion (both p < 0.001), and lymph node metastasis (7.5 % vs. 1.3 %, p = 0.009). Early recurrence was significantly associated with a higher prevalence of tumor necrosis (p = 0.002), aggressive vascular invasion (p = 0.006), satellite nodules (27.3 % vs. 6.9 %, p = 0.009), and advanced tumor stage (T3-T4: 27.3 % vs. 10.3 %, p = 0.003).
[CONCLUSION] Our findings suggest that HCC-related prognostic factors significantly influence cHCC-CC progression and recurrence, emphasizing that cHCC-CC may represent an aggressive variant of HCC.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
- Humans
- Carcinoma
- Hepatocellular
- Male
- Female
- Liver Neoplasms
- Cholangiocarcinoma
- Middle Aged
- Hepatectomy
- Retrospective Studies
- Prognosis
- Bile Duct Neoplasms
- Aged
- Neoplasm Recurrence
- Local
- Survival Rate
- Propensity Score
- Disease-Free Survival
- Adult
- Neoplasm Staging
- Combined hepatocellular cholangiocarcinoma
- Disease-free survival
- Early recurrence
- Hepatocellular carcinoma
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- A Phase I Study of Hydroxychloroquine and Suba-Itraconazole in Men with Biochemical Relapse of Prostate Cancer (HITMAN-PC): Dose Escalation Results.
- Self-management of male urinary symptoms: qualitative findings from a primary care trial.
- Clinical and Liquid Biomarkers of 20-Year Prostate Cancer Risk in Men Aged 45 to 70 Years.
- Diagnostic accuracy of Ga-PSMA PET/CT versus multiparametric MRI for preoperative pelvic invasion in the patients with prostate cancer.
- Association of patient health education with the postoperative health related quality of life in low- intermediate recurrence risk differentiated thyroid cancer patients.
- Early local immune activation following intra-operative radiotherapy in human breast tissue.